摘要
目的观察非小细胞肺癌患者血清可溶性E-钙粘素(sE-cad)、纤维蛋白原(Fig)、血小板表面α-颗粒膜蛋白(GMP-140)与活血化瘀药物临床疗效的相关性,研究活血化瘀药物在非小细胞肺癌患者治疗中的作用。方法对确诊为非小细胞肺癌的患者用随机数字表法分为治疗组和对照组,治疗组再按照"瘀血证候实验室指标"分为"活血组方治疗组"和"单纯化疗治疗组";对照组也按照"瘀血证候实验室指标"再分为"高凝血指标对照组"和"单纯对照组",统计分析四组患者的疗效。结果四组患者间治疗后的总有效率无统计学差异(P>0.05);sE-cad水平各组治疗前后无明显变化;A组应用活血化瘀药物后,FIB及GMP-140治疗后较治疗前有下降趋势(P<0.05);其他三组治疗前后FIB及GMP-140无统计学差异(P>0.05)。结论 sE-cad、Fig、GMP-140尚不能作为临床指导活血化瘀药物应用的实验室指标;以RECIST标准来评价恶性肿瘤疗效时,"活血组方"在非小细胞肺癌患者中无预期的疗效;但"活血组方"可以改善非小细胞肺癌患者血液高凝状态。
Objective To investigate the relationship between effect of blood activating and stasis removing drugs and indexes of E-cadherin(sE-cad),fibrinogen(Fig)and platelet surfaceα-granule membrane protein(GMP-140)in patients with non-small celllung cancer.Methods The patients with non-small cell lung cancer were randomly divided into treatment group and control group.The treatment group was divided into‘Huoxue group’and‘simple chemotherapy group’according to‘blood stasis syndrome laboratory index’.The control group was also divided into hypercoagulant index control group and simple control group according to‘blood stasis syndrome laboratory index’.The curative effect of the four groups was statistically analyzed.Results There was no statistical difference in the total effective rate of the four groups after treatment(P>0.05).There was no significant change in sE-cad level before and after treatment.In group A,FIB and GMP-140 showed a decreasing trend after the treatment(P<0.05).There was no significant difference in FIB and GMP-140 between the other three groups before and after treatment(P>0.05).Conclusion sE-cad,Fig and GMP-140 can not be used as a laboratory index to guide the application of drugs for promoting blood circulation and removing blood stasis.Evaluate by RECIST standard In the treatment of malignant tumor,‘Huoxue group prescription’has no expected effect in patients with non-small cell lung cancer,but‘Huoxue group prescription’can improve blood hypercoagulability in patients.
作者
王淑丽
陈文君
刘德山
WANG Shu-li;CHEN Wen-jun;LIU De-shan(Department of Geriatrics,Linyi People's Hospital,Linyi 276003,China;Department of Oncology,Linyi People's Hospital,Linyi 276003,China;Department of Traditional Chinese Medicine,Qilu hospital of Shandong University,Jinan 250012,China)
出处
《山东医学高等专科学校学报》
2018年第1期27-31,共5页
Journal of Shandong Medical College
基金
山东省中医药科学技术研究项目(2009-247)
关键词
非小细胞肺癌
瘀血症侯
活血化瘀药物
E-钙黏素
Non-small cell lung cancer
Blood stasis syndrome
Medicine for promoting blood circulation and removing blood stasis
E-cadherin
